SYDNEY, Australia, Aug. 28 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced that its Phase III B301 study of Bronchitol for the treatment of people with bronchiectasis has met its two primary efficacy endpoints: quality of life and mucus clearance.
Data from the 362 subject study demonstrated a highly significant improvement in quality of life after 12 weeks of treatment with Bronchitol as assessed by the St George Respiratory Questionnaire, a patient reported outcome tool for measuring health-related quality of life, (p-value less than 0.005) and a significant improvement in quality of life compared to placebo (p-value less than 0.05).
In addition, there was a highly significant difference in mucus clearance at 12 weeks for patients receiving Bronchitol versus those patients receiving placebo (p-value less than 0.001).
There were no serious adverse events attributable to treatment and the incidence of adverse events did not significantly differ between the placebo and the Bronchitol groups. The dropout rate overall was less than 10% indicating that treatment was well accepted.
The trial was conducted at 22 hospitals across Australia, New Zealand and the United Kingdom. Participants received either Bronchitol or placebo for 12 weeks, after which participants were provided with Bronchitol for a total of 12 months to determine the safety of long term treatment.
"The completion of this study and the achievement of its primary endpoints is a major advance towards our goal of having Bronchitol available for patients with bronchiectasis," said Pharmaxis Chief Executive Officer Dr Alan Robertson.
"This is the largest single study ever conducted in bronchiectasis and
we have collected a large amount of data on a variety of secondary
endpoints which are still being analyzed. With no products currently
indicated for bronchiectasis we look forward to discussing our complete
data set and next steps wi
|SOURCE Pharmaxis Ltd.|
Copyright©2007 PR Newswire.
All rights reserved